We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Zynquista

News List

Zynquista approved in EU for certain patients with type I diabetes pharmatimes
April 29, 2019
Sanofi has announced that its joint SGLT1/SGLT2 inhibitor with Lexicon, Zynquista (sotagliflozin), has been approved in Europe for certain patients with type I diabetes.
FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults with Type 1 Diabetes drugs
January 24, 2019
The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) today voted eight to eight on the question of ...
FDA to Review Zynquista (sotagliflozin) as Potential Treatment for Type 1 Diabetes drugs
May 31, 2018
The U.S. Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type 1 diabete